Study of Stool and Blood Markers to Detect Early Colorectal Cancer and Precancerous Polyps

What this Trial Is About

Researchers are studying colon cancer, which is the second most common cancer in men and women, focusing on early detection methods that may prevent the disease. This research evaluates whether stool or blood samples can detect colon cancers as early or earlier than colonoscopy by analyzing specific proteins called biomarkers. The study collects samples from people with colon cancer, adenomas, and those at risk to better understand and improve detection and prevention of colon and rectal cancer. The study collects stool, fecal immunochemical test FIT, serum, plasma, and tissue samples from about 1200 participants, including those with colorectal cancer, adenomas, higher risk without neoplasia, and average risk without neoplasia. These samples will be analyzed individually and combined to develop panels of markers to distinguish between healthy individuals and those with various stages of colon polyps or cancer. This research is part of a network funded by the National Cancer Institute to validate biomarkers for gastrointestinal cancers and improve screening tools. Participants will provide stool and blood samples and undergo colonoscopy results review. Researchers will collect data on the presence of DNA in biospecimens and compare new markers to the current standard FIT test. The study includes those with and without colorectal neoplasia and tracks clinical and tissue samples linked to patient data. Participant involvement may include sample collection, clinical assessments, and follow-up, with the total study duration varying by individual. The study aims to improve early detection methods through detailed biomarker research and sample banking.

Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas